Anavex Life Sciences Corp (AVXL)

[falconer66a]

Another Start-up Pharmaceutical Gets FDA Fast Track Designation

US Food and Drug Administration (FDA) has granted Fast Track designation for the development of FLX-787, the Company’s co-activator of TRPA1 and TRPV1, to treat severe muscle cramps in patients with ALS. There are currently no drugs approved in the US for this condition. Fast Track designation is intended to accelerate the clinical development and review of drugs to treat serious conditions that address an unmet medical need.

Flex Pharma, like Anavex, has new, proprietary, safe, and effective treatments for neurological conditions. Specifically, they treat the cramps and spasticity created by numerous nerve diseases.

Information here:
http://ir.flex-pharma.com/phoenix.zhtml?c=253862&p=irol-newsArticle&ID=2288469

Like Anavex, Flex Pharma is doing initial clinical trials in both the US and Australia, with new FDA oversight and endorsement (“fast track”).

Perhaps, just what will happen with Anavex 2-73. The parallels are close. New companies, with new, innovative, proprietary, no-side-effects drugs, that bring symptomatic relief.